AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00085709
Drug: gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV, induction Arm1 6mg/m2 D4; post-consolidation 5mg/m2 3 doses \>/= 28 days apart
Trial: NCT00085709
Drug: Cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV; induction Arms1/2 and reinduction 100 mg/m2/d days 1-7; consolidation 3gm/m2 q3hrs D1, 3, 5
Trial: NCT01711021
Drug: d-Amphetamine Transdermal Patch
RxNorm normalized name: amphetamine / dextroamphetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study was conducted in 2 parts: a 5 week, open-label, step-wise Dose Optimization Period and a 2-week, randomized, cross-over Double-Blind Treatment Period.~Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
Trial: NCT00085709
Drug: Daunomycin
RxNorm normalized name: Daunomycin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV; induction Arm1 45mg/m2 D1-3; Arm2 and reinduction 60 mg/m2 D1-3;
Trial: NCT04725422
Drug: Sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Trial: NCT04725422
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Trial: NCT04725422
Drug: Pamidronate
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Trial: NCT04725422
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Trial: NCT01499875
Drug: Phenoxymethylpenicillin
RxNorm normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mixture, 25 or 50 mg/kg taken once.
Trial: NCT04725422
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Trial: NCT02711956
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04725422
Drug: Certolizumab
RxNorm normalized name: certolizumab
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Trial: NCT04725422
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Trial: NCT04725422
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: second-line treatment for children with CNO/CRMO after failure to respond to NSAIDs
Trial: NCT04725422
Drug: NSAID
RxNorm normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: first-line treatment
Trial: NCT00353665
Drug: Memantine (Ebixa)
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg bid
Trial: NCT00279162
Drug: Calcipotriene/betamethasone gel and ointment
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01784133
Drug: omiganan
RxNorm normalized name: Omiganan
DrugBank: Omiganan (DB06610)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01578265
Drug: Ondansetron Tablets USP 8 mg
RxNorm normalized name: ondansetron Oral Tablet
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg tablet once a day
Trial: NCT01578265
Drug: Ondansetron Hydrochloride
RxNorm normalized name: Ondansetron Hydrochloride
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg tablet once a day
Trial: NCT00353665
Drug: riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: riluzole 50 mg bid
Trial: NCT04576325
Drug: Voriconazole Inhalation Powder
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules for a given dose must be inhaled over a maximum 10-minute period. Cohort 1 will receive 40 mg BID and Cohort 2 will receive 80 mg BID. Both Cohorts will administer study drug for 3.5 days (7 days total).
Trial: NCT01727401
Drug: Fondaparinux
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fondaparinux once daily sc injections at a dose of 2.5 mg if renal clearance of creatinine above 50 ml/min or Fondaparinux once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
Trial: NCT02188264
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02188264
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02554695
Drug: denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single subcutaneous injection of denosumab 60 mg
Trial: NCT00293215
Drug: 111-Indium-CMD-193
DrugBank: Indium (DB11659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 111-In-CMD-193 (3-7 mCi) was administered as an IV infusion over 60 (± 5) minutes.
Trial: NCT03683277
Drug: Ixazomib/Pomalidomide/Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment with association of Ixazomib, Pomalidomide and Dexamethasone (IPD)~Induction phase : 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged \<75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Treatment with association of Ixazomib and Pomalidomide (IP) Maintenance phase : 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21
Trial: NCT00586391
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For patients with intermediate or low grade leukemia/lymphoma, patients may receive ipilimumab once during the week 2 visit after the T cell infusion.
Trial: NCT00193908
Drug: Cavilon (TM) Durable Barrier Cream
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.
Trial: NCT02137083
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m2 D2 every 21 days
Trial: NCT02137083
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg D1, D15, D29, D57, every 28 days later
Trial: NCT00294723
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.8 mg for s.c. (under the skin) injection
Trial: NCT00294723
Drug: glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg capsule
Trial: NCT00294723
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.2 mg for s.c. (under the skin) injection
Trial: NCT02472392
Drug: Rabbit anti-thymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment
Trial: NCT02472392
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparitor
Trial: NCT02472392
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparitor
Trial: NCT02472392
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparitor
Trial: NCT02736227
Drug: Tacrolimus Withdrawal and Everolimus Monotherapy
RxNorm normalized name: Everolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: During the first month post-transplant, the subject receives everolimus (about 5-8 ng/mL) and tacrolimus with or without mycophenolic acid as part of standard of care procedures. At one month post-transplant, mycophenolic acid will be stopped and tacrolimus dosage will be reduced while continuing the dosage of everolimus. At three months post-transplant, tacrolimus dosage will be reduced by 50% of the daily dose each week. At four months post-transplant, tacrolimus will be discontinued.
Trial: NCT00752791
Drug: Peginesatide
RxNorm normalized name: Peginesatide
DrugBank: Peginesatide (DB08894)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginesatide 0.04 to 0.16 mg/kg, subcutaneous injection, once every 4 weeks for up to 25 weeks. Initial dose based on patient's previous total weekly Epoetin dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
Trial: NCT00279448
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On tablet of 25 mg per day during 5 years
Trial: NCT00279448
Drug: tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment
Trial: NCT00644228
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00644228
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00644228
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00521248
Drug: buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms
Trial: NCT00521248
Drug: Oral morphine solution
RxNorm normalized name: morphine Oral Tablet
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg/day morphine every 4 hours
Trial: NCT04161144
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
Trial: NCT02271555
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetic induction will be achieved via 8% sevoflurane
Trial: NCT02271555
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.
Trial: NCT02827903
Drug: Metformin + placebo
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Group II: Metformin + placebo,
Trial: NCT02336373
Drug: hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
Trial: NCT00428792
Drug: Methylphenidate 20 mg long-acting capsules
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03404115
Drug: Reproxalap Ophthalmic Solution (0.25%)
RxNorm normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproxalap Ophthalmic Solution (0.25%) administered for approximately twelve weeks.
Trial: NCT03404115
Drug: Reproxalap Ophthalmic Solution (0.1%)
RxNorm normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproxalap Ophthalmic Solution (0.1%) administered for approximately twelve weeks.
Trial: NCT03404115
Drug: Vehicle Ophthalmic Solution
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution administered for approximately twelve weeks.
Trial: NCT03519256
Drug: BMS-986205
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT03643107
Drug: Irofulven
RxNorm normalized name: Irofulven
DrugBank: Irofulven (DB05786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone.
Trial: NCT03921073
Drug: T-VEC
RxNorm normalized name: T-Vec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive intralesional injections of T-VEC of up to 4cc. Dosing of T-VEC is dependent of the size of the lesion.
Trial: NCT03386578
Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/300 mg of FTC/TDF administered orally as a fixed-dose combination tablet once daily
Trial: NCT04292769
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 10mg / d, intravenous administration d-5 ～ d-1
Trial: NCT02758132
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 160 mg enzalutamide by mouth daily
Trial: NCT02758132
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg abiraterone by mouth daily
Trial: NCT02758132
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg prednisone by mouth twice daily
Trial: NCT02285647
Drug: Rolapitant - Oral
DrugBank: Rolapitant (DB09291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
Trial: NCT02285647
Drug: Rolapitant - IV
DrugBank: Rolapitant (DB09291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
Trial: NCT01136031
Drug: Paclitaxel and irinotecan
RxNorm normalized name: Paclitaxel
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In phase I part, Level Paclitaxel (mg/m²) Irinotecan (mg/m²)~1. 100 100~2. 100 120~3. 135 120~4. 135 160~every 3 week
Trial: NCT03509883
Drug: Drug: Apixaban sprinkle capsules
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose (25 x 0.1 mg capsules), oral administration
Trial: NCT03509883
Drug: Experimental: Apixaban tablets followed by apixaban sprinkle capsules
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Apixaban sprinkle capsules Single dose (25 x 0.1 mg capsules), oral administration
Trial: NCT00810914
Drug: bupivicaine epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivicaine continuous epidural infusion
Trial: NCT00810914
Drug: bupivicaine epidural infusion patient epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivicaine
Trial: NCT00810914
Drug: bupivicaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient controlled anesthesia only
Trial: NCT02833610
Drug: Denosumab Q4W
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02154737
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
Trial: NCT02154737
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg.
Trial: NCT00672022
Drug: Zavesca (Miglustat)
RxNorm normalized name: miglustat Oral Capsule [Zavesca]
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02387138
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels).
Trial: NCT02387138
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle
Trial: NCT02387138
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle
Trial: NCT03905291
Drug: MT921
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Formulated as an injectable solution
Trial: NCT03028103
Drug: Tazemetostat
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tazemetostat is a selective oral small molecule inhibitor of EZH2
Trial: NCT03028103
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat
Trial: NCT03028103
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.
Trial: NCT03028103
Drug: Repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.
Trial: NCT03917459
Drug: Enalapril matching placebo
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo to Enalapril 10 mg film-coated tablets
Trial: NCT03917459
Drug: Enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg film-coated tablets
Trial: NCT00409890
Drug: Hyoscine Butyl Bromide
RxNorm normalized name: Butyl Alcohol
DrugBank: Butyl alcohol (DB02145)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03449082
Drug: Fibrin glue
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue 0.5cc
Trial: NCT01665170
Drug: Passiflora incarnata
RxNorm normalized name: Passiflora incarnata
DrugBank: Passiflora incarnata flower (DB13974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 1 tablet per day for 3 days
Trial: NCT04137029
Drug: Formoterol
RxNorm normalized name: Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The participants will receive inhalation of formoterol 12 micrograms
Trial: NCT04137029
Drug: Tiotropium Bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participants will receive inhalation of tiotropium bromide 18 mkg once